-
In the dance of who does what with Duchenne, it’s OK to ask for help
“What can I do to help?” It was my husband’s answer to the long rant
-
PPMD 2024: Trials due for DMD gene therapies, cell regeneration
In its 30-year history, Parent Project Muscular Dystrophy (PPMD) has helped fund the development of
-
PPMD 2024: 4 therapies aiming to slow DMD progression now in trials
Four experimental treatments — deramiocel, sevasemten, satralizumab, and tadalafil — all in clinical testing and
-
A rough month makes me grateful for what I’ve got
Last month was tough for me. Although celebrating my partner’s birthday on June 12 was
-
Seminario Web Cure Duchenne: Explicación de la Decisión de la FDA acerca de Elevidys
Watch HERE The post Seminario Web Cure Duchenne: Explicación de la Decisión de la FDA
-
FDA APPROVAL OF ELEVIDYS
This webinar discusses a groundbreaking gene therapy treatment for Duchenne Muscular Dystrophy (DMD), focusing on
-
Dyne Therapeutics of DYNE-251 in Duchenne
Dyne Therapeutics shares with the community recent efficacy and safety data from the ongoing DELIVER
-
ITF THERAPEUTICS| DUVYZAT Update
CureDuchenne Webinar | ITF THERAPEUTICS Patient Community Update: An overview of DUVYZAT Recorded on June
-
PPMD 2024: Building community is vital for mental, physical health
Connecting with a supportive community is essential for people affected by muscular dystrophy to maintain both
-
PPMD 2024: PTC to seek FDA approval of ataluren for DMD
PTC Therapeutics plans to soon ask the U.S. Food and Drug Administration (FDA) to approve
